Skip to main content

Table 3 Adverse events

From: Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone

 

The LAC group

n = 13

The HAC group

n = 7

Myelosuppression

  

< 3 Grade

5 (38.46%)

3 (42.86%)

≥ 3 Grade

2 (15.38%)

2 (28.57%)

total

7 (53.85%)

5 (71.43%)

Pneumonia

3 (23.08%)

2 (28.57%)

 
  1. LAC, low-dose Ara-c chemotherapy; HAC, high-dose Ara-c chemotherapy
Back to article page

BMC Pediatrics

ISSN: 1471-2431

Contact us